Navigation Links
OncoTAb to Highlight a Tumor Specific Marker to Enable Earlier Detection of Breast Cancer in Women with Dense Breasts at 2015 SABCS
Date:12/10/2015

OncoTAb, Inc., a University of North Carolina at Charlotte (UNCC) spin-out company, announced it will present scientific data highlighting a non-invasive blood test to aid in the early detection of breast cancer in women with dense breast tissue. The technology utilizes a monoclonal antibody that is specific to all major breast cancer subtypes, including triple negative breast cancer (TNBC). The presentation, “A monoclonal antibody with exceptional specificity across major breast cancer subtypes,” will take place on Friday, Dec. 11 at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

“The data, which includes results from 486 patient samples, demonstrates that this monoclonal antibody recognizes a tumor specific marker in the serum and tissue, regardless of breast subtypes or breast tissue density,” quotes Pinku Mukherjee, OncoTAb Co-founder & Chief Science Officer, and Mayo Clinic Alumna. “The data clearly demonstrates that this antibody can be used to target tumors in vivo with promising imaging and therapeutic applications, including the development of Chimeric Antigen Receptor (CAR) engineered T-cells for TNBC.” she added.

“We have been able to use this novel, patented antibody to personalize the blood serum marker levels and build an early detection strategy around it for women with dense breast tissue,” said OncoTAb CEO Rahul Puri. “The Agkura™ Personalized Score increases with disease progression and will be available in 2016 as a non-invasive and affordable blood test supplemental to mammography. This early detection strategy has received overwhelming support from clinicians, breast density advocates and women concerned about their high tissue density and low mammography sensitivity.”

Logistics of the featured presentation at SABCS are below. Follow OncoTAb on Twitter @OncoTab.

Title: A monoclonal antibody with exceptional specificity across major breast cancer subtypes. Date: Friday, Dec. 11, 2015: 7:30 to 9:00 a.m. CT. Poster: P4-09-16

This press release is neither an offer to sell nor the solicitation of an offer to buy shares or any other security in any jurisdiction.

About OncoTAb, Inc.

OncoTAb (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNCC) spin-out company that has a patent-protected technology. Its applications span the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up to launch its blood test to aid in the early detection of breast cancer in women with dense breast tissue. OncoTAb is in early stages of developing therapeutic applications, including development of Chimeric Antigen Receptor (CAR) engineered T-cells for Triple Negative Breast Cancer. The company is seeking to partner/license its technology for the development of an imaging application to detect cancer in women with dense breast tissue.

Read the full story at http://www.prweb.com/releases/2015/12/prweb13124107.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related biology technology :

1. OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award
2. OncoTAb Names Dr. David L. Cooper as COO
3. CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc.
4. A Large Prevalent Population and the Lack of an Approved Therapeutic Highlight Lucrative Market Opportunity in Nonalcoholic Steatohepatitis
5. MEI Pharma Highlights New Data from Phase II Clinical Studies of Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome
6. Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting
7. GenVec Highlights Gorilla Adenovectors At Vaccines R&D-2015 Conference
8. Veracyte Announces Data to be Presented at PFF Summit 2015 Highlighting IPF Diagnostic Challenges and Potential of New Genomic-Based Testing Approaches
9. Neuroscience and Laser Materials Among Highlights for SPIE Photonics West 2016
10. Presentations to Highlight BioLights IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences
11. MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
(Date:10/6/2017)... Mass. (PRWEB) , ... October 06, 2017 , ... ... female entrepreneurship within the healthcare and technology sector at their fourth annual Conference ... panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):